caa a22 4500 606185798 CHVBK 20210128100833.0 cr unu---uuuuu 210128e20150401xx s 000 0 eng 10.1007/s00405-014-2937-2 doi (NATIONALLICENCE)springer-10.1007/s00405-014-2937-2 Influence of risk grouping on therapeutic decisions in patients with anaplastic thyroid carcinoma [Elektronische Daten] [Chuanzheng Sun, Chao Li, Zedong Hu, Xiaojiang Li, Jiehua He, Ming Song, Guojun Li, Fenghua Zhang, Qiuli Li] We investigated prognostic factors in 42 anaplastic thyroid carcinoma (ATC) patients from a single institution over a 30-year period and explored the use of risk grouping to guide therapeutic decisions. Univariable and multivariable differences in overall survival (OS) were evaluated using the Kaplan-Meier method and the log-rank test as well as Cox proportional hazards model. Risk grouping in making therapeutic decisions for ATC patients was explored. The 1- and 3-year OS rates were 28.6% and 18.5%, respectively. Univariate analysis indicated that 4 pre-therapeutic factors of patients were related to poorer prognoses: age≥55years, white blood cell count≥10.0×109/L, blood platelet count≥300.0×109/L and advanced clinical tumor-node-metastasis stage. These factors were used to calculate the risk indices. Patients with total risk index scores of no more than 1 were considered to be in the low-risk group, and patients with scores≥2 were considered to be in the high-risk group. The patients in the low-risk group had significantly better 1- and 3-year OS rates (90.9% and 63.6%, respectively) than those in the high-risk group (6.5% and 3.2%, respectively). Risk group and therapeutic regimen were the 2 factors that independently influenced survival according to multivariable analysis. Surgery that was combined with postoperative radiotherapy significantly benefited the patients in the low-risk group rather than the patients in the high-risk group. Risk grouping was a helpful tool of evaluating the prognoses and guiding the treatment of ATC patients. Springer-Verlag Berlin Heidelberg, 2014 Anaplastic thyroid carcinoma nationallicence Risk grouping nationallicence Therapeutic decisions nationallicence White blood cell count nationallicence Blood platelet count nationallicence Sun Chuanzheng Department of Head and Neck Surgery, The Third Affiliated Hospital of Kunming Medical University, 519 Kunzhou Road, Kunming, China aut Li Chao Department of Head and Neck Surgery, The Tumor Hospital of Sichuan Province, 55 Renmin Road South, Chengdu, China aut Hu Zedong Department of Head and Neck Surgery, The Third Affiliated Hospital of Kunming Medical University, 519 Kunzhou Road, Kunming, China aut Li Xiaojiang Department of Head and Neck Surgery, The Third Affiliated Hospital of Kunming Medical University, 519 Kunzhou Road, Kunming, China aut He Jiehua State Key Laboratory of Oncology in South China, 651 Dongfeng Road East, Guangzhou, China aut Song Ming Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, 510060, Guangzhou, China aut Li Guojun Department of Head and Neck Surgery, Unit 1445, The University of Texas MD Anderson Cancer Center, TX 77030, Houston, USA aut Zhang Fenghua Department of General Surgery, The Second Hospital of Hebei Medical University, 050000, Shijiazhuang, Hebei, China aut Li Qiuli Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, 510060, Guangzhou, China aut European Archives of Oto-Rhino-Laryngology Springer Berlin Heidelberg 272/4(2015-04-01), 985-993 0937-4477 272:4<985 2015 272 405 https://doi.org/10.1007/s00405-014-2937-2 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00405-014-2937-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Sun Chuanzheng Department of Head and Neck Surgery, The Third Affiliated Hospital of Kunming Medical University, 519 Kunzhou Road, Kunming, China aut NATIONALLICENCE 700 1- Li Chao Department of Head and Neck Surgery, The Tumor Hospital of Sichuan Province, 55 Renmin Road South, Chengdu, China aut NATIONALLICENCE 700 1- Hu Zedong Department of Head and Neck Surgery, The Third Affiliated Hospital of Kunming Medical University, 519 Kunzhou Road, Kunming, China aut NATIONALLICENCE 700 1- Li Xiaojiang Department of Head and Neck Surgery, The Third Affiliated Hospital of Kunming Medical University, 519 Kunzhou Road, Kunming, China aut NATIONALLICENCE 700 1- He Jiehua State Key Laboratory of Oncology in South China, 651 Dongfeng Road East, Guangzhou, China aut NATIONALLICENCE 700 1- Song Ming Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, 510060, Guangzhou, China aut NATIONALLICENCE 700 1- Li Guojun Department of Head and Neck Surgery, Unit 1445, The University of Texas MD Anderson Cancer Center, TX 77030, Houston, USA aut NATIONALLICENCE 700 1- Zhang Fenghua Department of General Surgery, The Second Hospital of Hebei Medical University, 050000, Shijiazhuang, Hebei, China aut NATIONALLICENCE 700 1- Li Qiuli Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, 510060, Guangzhou, China aut NATIONALLICENCE 773 0- European Archives of Oto-Rhino-Laryngology Springer Berlin Heidelberg 272/4(2015-04-01), 985-993 0937-4477 272:4<985 2015 272 405